STUDY GUIDE TEST 4
Direct Antiglobulin Test (DAT) Study Guide
1. Principle of the Antiglobulin Test
IgM antibodies:
Readily cause visible agglutination
IgG antibodies:
Do NOT cause agglutination on their own
How IgG is detected
Add anti-human globulin (AHG), which binds to the Fc portion of IgG
AHG is also called:
Coomb’s antibody
Coomb’s serum
“The green stuff”
What happens in the test
After centrifugation:
AHG forms a bridge between IgG-coated red blood cells
This creates visible agglutination
2. When is AHG Testing Used?
Antibody screening & identification
Detects antibodies against non-ABO antigens
Positive results require further testing before transfusion
Antigen typing
Determines if donor RBCs have certain antigens
Helps select compatible blood
Direct antiglobulin testing (DAT)
Detects in vivo coating of RBCs
Used when suspecting:
Hemolytic Disease of the Fetus and Newborn (HDFN)
Autoimmune Hemolytic Anemia (AIHA)
Hemolytic Transfusion Reaction (HTR)
3. Direct vs. Indirect Antiglobulin Test
Direct Antiglobulin Test (DAT)
Detects:
RBCs coated in vivo
Uses:
Patient RBCs
Purpose:
Determines if RBCs are already coated with IgG or complement
Indirect Antiglobulin Test (IAT)
Detects:
Antibodies in serum
Uses:
Patient serum + reagent RBCs
Purpose:
Detects unexpected antibodies
Determines antigen presence
Key Difference
DAT → In vivo coating
IAT → In vitro reaction
4. Direct Antiglobulin Test (DAT) Details
What DAT Detects
IgG coating
Complement (C3b, C3d)
Both IgG and complement
What DAT Does NOT Detect
IgM (unless complement activated)
IgA
Control
Patient RBCs + saline
If positive → suggests polyagglutination
5. Specimen Requirements
Use lavender top tube (EDTA)
EDTA chelates:
Calcium (Ca++)
Magnesium (Mg++)
Prevents complement activation in vitro
Ensures any complement detected occurred in vivo
6. DAT Procedure
Steps
Start with polyspecific AHG reagent
If positive:
Repeat using monospecific reagents
Prepare fresh cell suspension
Important Step
If C3 test is negative:
Add complement-coated check cells
7. Interpretation of DAT Results
Positive DAT Indicates
RBCs are coated with antibody and/or complement
Associated Conditions
HDFN
Maternal antibodies coat fetal RBCs
HTR
Recipient antibodies coat donor RBCs
AIHA
Autoantibodies coat own RBCs
Types:
Warm
Cold
Paroxysmal Cold Hemoglobinuria (PCH)
Drug-induced hemolysis
8. Follow-Up to a Positive DAT
Clinical Evaluation
Diagnosis
Medications
Recent transfusions
Lab Values
Hematocrit & hemoglobin
Bilirubin
LDH
9. Elution
Definition
Process of removing antibodies from coated RBCs
How it Works
Breaks antigen-antibody bond
Releases antibody into solution (eluate)
Purpose
Identify antibody specificity
Test eluate against reagent RBC panels
10. Key Concepts to Remember
IgG needs AHG to agglutinate
DAT detects in vivo sensitization
EDTA prevents false complement activation
Positive DAT requires clinical follow-up
Elution helps identify the antibody causing the reaction
Hemolytic Disease of the Fetus & Newborn (HDFN) Study Guide
1. Definition & Characteristics of HDFN
HDFN is a condition where:
Fetal or neonatal RBCs have a shortened lifespan
Caused by maternal IgG antibodies binding to fetal RBCs
2. Pathophysiology of HDFN
Basic Mechanism
Maternal IgG crosses the placenta
IgG binds to fetal RBC antigens
Coated RBCs are destroyed by:
Macrophages in spleen and liver
Leads to extravascular hemolysis
Effects on the Fetus
Anemia
Increased RBC production by bone marrow
Release of NRBCs into circulation
Extramedullary hematopoiesis
Hepatosplenomegaly
Cardiac failure
Advanced Complications
Hypoproteinemia
Hydrops fetalis
Bilirubinemia
After Birth
Accumulation of unconjugated bilirubin
Due to immature liver
Causes:
Jaundice
Risk of kernicterus (brain toxicity)
3. Causes of HDFN
Requirements for HDFN to Occur
Mother exposed to foreign antigen
Mother produces antibody
Antibody is IgG
Fetus has the corresponding antigen
Exposure Sources
Previous pregnancy
Transfusion
Transplacental Hemorrhage Causes
Before delivery:
Abortion, ectopic pregnancy, amniocentesis, CVS
At delivery:
C-section, manual placenta removal, prolonged delivery
Other:
Trauma, transfusion
4. Antibodies Involved in HDFN
Most Severe
Anti-D
Most Common
Rh system: D, E, c
Kell
ABO
Less Common
Kidd
Duffy
Ss (rare)
5. Laboratory Role in HDFN
Maternal Testing
First visit:
ABO, Rh, antibody screen
If Rh negative:
Repeat screen at 28 weeks
If antibody present:
Antibody identification and titers
Monitor every 2–4 weeks
Paternal Testing
Determines fetal risk:
Homozygous → baby definitely has antigen
Heterozygous → 50% chance
Negative → no risk
Amniotic Testing
Detect:
Fetal antigens
Blood type
Bilirubin levels (hemolysis severity)
Cordocentesis (PUBS)
Umbilical blood sampling
Determines
Hemoglobin & hematocrit
Blood type
Antigen phenotype
DAT
Newborn Testing
Bilirubin
DAT
ABO/Rh typing
CBC
Hemoglobin & hematocrit
RBC morphology:
NRBCs
Polychromasia
Spherocytes
6. ABO vs Non-ABO HDFN
ABO HDFN
~15% of pregnancies at risk
Usually:
Type O mother with A or B baby
Characteristics:
Mild severity
Can occur in first pregnancy
Appears 12–48 hours after birth
Treatment:
Phototherapy
Non-ABO HDFN
More severe
Usually not first pregnancy
Caused by:
Prior sensitization (pregnancy/transfusion)
Antigen inherited from father
Affects all future pregnancies with antigen-positive fetus
7. Rh (D) HDFN
Risk Situation
Mother: Rh negative
Father: Rh positive
Baby: may be Rh positive
What Happens
Mother exposed to D antigen
Produces Anti-D
Anti-D crosses placenta and destroys fetal RBCs
8. Rh Immune Globulin (RhIg)
What It Is
Injectable Anti-D IgG
How It Works
Binds fetal D+ cells in maternal circulation
Macrophages remove them
Prevents maternal immune response
Prevents formation of maternal Anti-D
Dosage
300 µg:
Covers 15 mL packed RBCs (30 mL whole blood)
50 µg (microdose):
Covers 2.5 mL packed RBCs
When RhIg is Given
26–28 weeks gestation
Within 72 hours after delivery
After:
Amniocentesis
PUBS
Abortion
Trauma
When RhIg is NOT Given
Mother is Rh positive
Mother already has Anti-D
Baby is Rh negative
Lab Complication
Passive Anti-D can cause:
Positive antibody screen up to 3 months
9. Neonate Testing
Cord blood tested for:
ABO typing
Rh typing (including weak D)
DAT
Important
Positive DAT:
Indicates antibody-coated RBCs
Invalidates weak D test
10. Elution
Removes antibodies from RBCs
Allows identification of antibody specificity
11. Tests for Fetomaternal Hemorrhage (FMH)
Rosette Test (Screening)
Detects D+ fetal cells in maternal blood
Interpretation:
≥3 rosettes/5 fields → Positive
<3 → Negative
Kleihauer-Betke Test (Quantitative)
Based on:
Fetal cells contain HbF
Resistant to acid
Results:
Fetal cells = bright pink
Maternal cells = ghost-like
Calculation
% fetal cells × 50 = volume of FMH (mL)
FMH ÷ 30 = number of RhIg vials
Always add 1 vial
12. Treatment of HDFN
Phototherapy
Used for mild cases
UV light breaks down bilirubin
“Bili light” or “bili blanket”
Intrauterine Transfusion
For fetal anemia or hydrops
Blood given via umbilical vein
Goal:
Maintain Hb > 10 g/dL
Done every 2–4 weeks
Exchange Transfusion
After birth
Removes:
Bilirubin
Maternal antibodies
Coated RBCs
Replaces with donor blood
13. Key Concepts to Remember
HDFN requires IgG antibodies
Severity depends on antigen type
Anti-D is most severe
RhIg prevents sensitization
DAT confirms coated fetal RBCs
FMH testing determines RhIg dose
Treatments focus on:
Reducing bilirubin
Replacing RBCs
Preventing complications
Blood Donation Process Study Guide
1. Blood Product Manufacturing Process Flow
Blood is collected from donor
Samples drawn for testing
Blood sent to donor center
Processed into components:
Red blood cells
Platelets
Plasma
Cryoprecipitate
Labeled and stored
Released for transfusion after testing
2. Blood Usage & Supply Facts
Every 2 seconds someone in the U.S. needs blood
41,000+ donations needed daily
30 million components transfused yearly
One donation can help up to 3 people
Blood cannot be manufactured
Type O-negative:
Universal donor (RBCs)
High demand, short supply
AB plasma:
Universal plasma donor
Less than 10% of eligible people donate
3. Types of Blood Donations
Allogeneic Donation
Blood donated for use by others
Autologous Donation
Donor gives blood for self-use
Characteristics:
Can donate every 3 days (1 week recommended)
Minimum hematocrit: 33%
Advantages:
No antibody formation
No infectious disease transmission
Increased patient confidence
Limitation:
Can only be used for that patient
Directed Donation
Donor gives blood for a specific person
Not necessarily safer
Must meet all donor requirements
Special considerations:
Must be irradiated if from relative (risk of GVHD)
Mothers discouraged donating to children
Husbands discouraged donating to wives (risk of HDFN)
4. Apheresis Process
Blood collected via machine
Machine separates components
Specific components collected:
Platelets
Plasma
Red cells
Remaining blood returned to donor
Takes longer than whole blood donation
5. Donation Frequency Limits
Whole blood (RBCs):
Every 56 days
Double RBCs:
Every 112 days
Platelets:
Every 7 days
Max 24 times/year
Autologous:
Every 3 days (recommended weekly)
6. Donor Eligibility Requirements
General Requirements
Good health
Feeling well
Minimum age:
17 years old
16 with parental consent (allowed in Arkansas)
Minimum weight:
110 lbs
Hemoglobin Requirement
Minimum:
12.5 g/dL
Most common reason for deferral:
Low hemoglobin/hematocrit
Additional Factors
Travel history
Health history
Vital signs checked:
Temperature
Pulse
Blood pressure
7. Four Steps of Blood Donation Process
Step 1: Registration
Sign-in process
Review eligibility
Show ID
Read donation information
Step 2: Health History & Mini-Physical
Confidential interview:
Health history
Travel history
Mini-physical includes:
Temperature
Pulse
Blood pressure
Hemoglobin
Step 3: Donation (Phlebotomy)
Procedure
Arm cleaned
Sterile needle inserted
Blood collected (~1 pint)
Timing
Donation: 8–10 minutes
Entire visit: ~1 hour 15 minutes
Collection Details
First 30–40 mL diverted
Used for testing or discarded
Multiple tubes collected for testing
Blood bag system:
4 connected bags
Contains anticoagulant
Step 4: Refreshments
Rest 10–15 minutes
Eat and drink
Resume normal activities
Recovery:
Plasma: 24 hours
RBCs: weeks
8. Blood Components & Storage
Components
Red blood cells
Platelets
Plasma
Cryoprecipitate
Shelf Life
RBCs: 42 days
Platelets: 5 days
Plasma/cryo: up to 1 year (frozen)
9. Laboratory Testing on Donated Blood
All Units Tested For
HIV 1 & 2
Hepatitis B
Hepatitis C
Syphilis
HTLV-I/II
West Nile Virus
Trypanosoma cruzi
Babesia
CMV
COVID
10. Whole Blood Donation Labeling
Unique donor number
Blood product type
Anticoagulant used
Volunteer donor statement
Blood type and expiration added after testing
11. Special Donation Types
Double Red Cell Donation
Higher requirements:
Males:
≥5’1”, ≥130 lbs
Females:
≥5’5”, ≥150 lbs
Intra-Operative Autologous Collection
“Cell saver”
Blood collected during surgery
Reinfused to patient
Must be used within 24 hours
12. Key Concepts to Remember
Blood donation is a safe, sterile process
One donation can save up to 3 lives
Apheresis allows targeted component collection
Strict eligibility and testing ensure safety
Blood has limited shelf life, especially platelets
Donation frequency depends on component type
Testing prevents infectious disease transmission
Blood Component Preparation Study Guide
1. Overview of Blood Components
Whole blood is separated into:
Red blood cells (RBCs)
Plasma
Platelets
From one donation → 3 main components produced
2. Blood Collection & Initial Preparation
Collection System
4-bag system connected by tubing
~500 cc whole blood collected
Mixed with 70 mL CPD
CPD Components
Citrate → anticoagulant
Phosphate → buffer, supports ATP production
Dextrose → nutrient
3. Component Separation Process
Primary Separation (Soft Spin)
Separates:
RBCs
Platelet-rich plasma (PRP)
Secondary Separation (Hard Spin)
PRP separated into:
Platelets
Plasma
4. Red Blood Cells (RBCs)
Preparation
PRP removed
Add additive solution
Store at 1–6°C
RBCs in CPD
Volume: 200–250 mL
Hematocrit: 75–85%
Expiration: 21 days
RBCs with Additive Solution
Volume: 300–350 mL
Hematocrit: 55–60%
Expiration: 42 days
Additive Solution Contains
Adenine → ATP production
Saline + dextrose → nutrients
Mannitol → membrane stability
Citrate compounds
Clinical Use
Increase oxygen-carrying capacity
Used for:
Blood loss >25%
Anemia (Hct <26%)
1 unit RBC → ↑ Hct by ~3%
5. RBC Storage & “Storage Lesion”
Changes During Storage
↓ Glucose
↓ pH
↓ ATP
↓ 2,3-DPG
↓ Sodium
↑ Potassium
Slight ↑ hemolysis
Glycolytic Pathway Impact
Glucose consumed → acid produced
Acid ↓ 2,3-DPG
↓ 2,3-DPG → impaired O₂ delivery
↓ ATP → shortened RBC lifespan
Key Point
ATP level = main factor in RBC effectiveness
2,3-DPG restored 24 hrs after transfusion
6. Special Types of RBCs
Fresh RBCs (<5 days old)
Used for:
Intrauterine transfusions
Neonates (<4 months)
Pediatric surgeries
Sickle cell patients
Leukoreduced RBCs
WBCs removed via filtration
Benefits:
↓ cytokines
↓ CMV transmission
↓ febrile transfusion reactions
↓ immune sensitization
Indications:
Organ transplant patients
Chronically transfused patients
Prior febrile reactions
Cardiac surgery patients
Irradiated RBCs
Exposed to 25 Gy radiation
Prevents T-cell proliferation
Purpose:
Prevent graft-versus-host disease (GVHD)
Indications:
Immunocompromised patients
Bone marrow/stem cell transplant
Intrauterine transfusions
Leukemia/blood cancers
AIDS
Blood from relatives
HLA-matched products
7. Platelets
Random Donor Platelets (RDP)
Stored at 20–24°C
Kept in constant motion
Given in pools (4–6 units; standard = 4)
Effect
↑ platelet count by 25,000–50,000
Compatibility
ABO
Platelets have few ABO antigens
Plasma contains antibodies
Prefer ABO-compatible plasma
Rh
Platelets have no Rh antigens
RBC contamination may cause sensitization
Give Rh-negative platelets to:
Rh-negative females of childbearing age
Apheresis Platelets
From single donor
Equivalent to 4–5 random donors
Advantages:
↓ alloimmunization
↓ infection risk
Can be HLA matched
Storage
Same as RDP:
5 days
Room temp with agitation
8. Platelet Bacterial Contamination
Risk
~0.1–0.2% contaminated
Common organisms:
Skin flora
Prevention (Donor Center)
Skin cleansing
First 30–50 mL diverted
Detection (Transfusion Center)
Culture (standard)
pH & glucose testing
PCR (most effective)
9. Plasma
Fresh Frozen Plasma (FFP)
Contains all clotting factors
Frozen within 8 hours
Storage
Frozen: -18°C (1 year)
Thawed: 1–6°C (24 hours)
24-Hour Plasma
Frozen within 24 hrs (not 8 hrs)
Slightly ↓ factors V & VIII
Used interchangeably with FFP
Thawed Plasma
If not used in 24 hrs:
Relabeled
Can be used up to 5 days
Deficient in factors V & VIII
Special Note
Male plasma preferred:
Avoid HLA antibodies from pregnancy
10. Cryoprecipitate
Contents
Factor VIII (≥80 IU)
Fibrinogen (≥150 mg)
von Willebrand factor
Factor XIII
Uses
DIC
Hemophilia A
Fibrin glue
Preparation
Made from FFP
Thawed at 4°C
Refrozen at -18°C
Storage
Frozen: 1 year
Thawed:
20–24°C
6 hours (4 hours if pooled in lab)
Administration
Small volume: 10–20 mL
Usually pooled (≈10 units)
Pre-pooled Product Advantages
Faster availability
Less labor
Longer post-thaw time
11. Key Concepts to Remember
Whole blood → separated into RBCs, plasma, platelets
Soft spin vs hard spin determines separation
RBC storage leads to biochemical changes (storage lesion)
ATP and 2,3-DPG are critical for RBC function
Platelets require room temp + agitation
Plasma must be frozen quickly to preserve factors
Cryoprecipitate is factor-rich concentrate
Special RBC products prevent:
Infection
Immune reactions
GVHD
Transfusion Reactions Study Guide
1. Overview of Transfusion Reactions
Definition
An undesirable result of a blood transfusion
Often caused by an immune (antigen-antibody) reaction
Antibodies may target:
Red cells
White cells
Platelets
Plasma proteins
Key Concept
Transfusions are inherently risky
Cannot always be predicted or prevented
Must:
Weigh risks vs benefits
Obtain informed consent
Only transfuse when necessary
2. Categories of Transfusion Reactions
Hemolytic
Acute Hemolytic Transfusion Reaction (AHTR)
Delayed Hemolytic Transfusion Reaction (DHTR)
Non-Hemolytic
Allergic
Febrile non-hemolytic
Anaphylactic
TRALI
TACO
GVHD
3. General Clinical Symptoms
Mild–Moderate
Fever, chills
BP changes
Dyspnea
Urticaria (hives)
Nausea/vomiting
Wheezing
Pain (infusion site, back)
Red urine
Anxiety
Severe
Renal failure
Respiratory arrest
Cardiac arrest
Shock
DIC
Death
HEMOLYTIC TRANSFUSION REACTIONS
4. Acute Hemolytic Transfusion Reaction (AHTR)
Cause
ABO incompatibility
Usually due to human error
Pathophysiology
Recipient antibodies react with donor RBCs
Activates complement cascade
Leads to intravascular hemolysis
Onset
Minutes to hours
Symptoms
Fever (most common)
Chills
Back/flank pain
Hypotension
Dyspnea
Hemoglobinuria
“Feeling of doom”
Severe → shock, DIC, renal failure
Key Facts
Can occur with as little as 10 mL incompatible blood
Severity depends on amount transfused
Treatment
Immediate recognition
Maintain blood pressure
Correct coagulopathy
Maintain urine flow
5. Delayed Hemolytic Transfusion Reaction (DHTR)
Cause
Secondary immune response
Antibody previously formed but undetectable
Pathophysiology
Antigen-positive donor cells transfused
Antibody production increases
Extravascular hemolysis (liver/spleen)
Onset
Days to weeks
Symptoms
Fever
Anemia
Jaundice
No rise in hematocrit
Lab Findings
↓ Hematocrit
↑ Bilirubin
↑ LDH
Blood smear:
Spherocytes
Reticulocytes
DAT:
Positive or negative
Antibody screen:
May be positive or negative
Treatment
Monitor patient
Correct anemia
Future transfusions:
Use antigen-negative blood
NON-HEMOLYTIC TRANSFUSION REACTIONS
6. Allergic Reactions
Cause
Hypersensitivity to plasma proteins
Pathophysiology
IgE-mediated
Mast cell degranulation → histamine release
Onset
Seconds to minutes
Symptoms
Urticaria
Watery eyes
Runny nose
Angioedema
Treatment
Stop transfusion temporarily
Give Benadryl
Resume if symptoms resolve
Prevention
Premedication (Benadryl)
7. Anaphylactic Reaction
Cause
Often IgA deficiency with anti-IgA antibodies
Pathophysiology
Severe IgE-mediated reaction
Symptoms
Airway swelling
Hypotension
Shock
Rapid weak pulse
Treatment
Stop transfusion immediately
Maintain airway & oxygenation
Prevention
Autologous blood
Washed RBCs/platelets
IgA-deficient donor plasma
8. Febrile Non-Hemolytic Reaction (FNHTR)
Definition
Temperature rise >1°C
Cause
Antibodies to WBC antigens
Cytokine release
Symptoms
Fever
Chills
Anxiety
BP changes
Treatment
Stop transfusion
Give acetaminophen
Prevention
Leukoreduction
Premedication
9. TRALI (Transfusion-Related Acute Lung Injury)
Cause
Donor antibodies to recipient WBCs
Pathophysiology
Immune complexes damage lung capillaries
↑ permeability → pulmonary edema
Onset
1–2 hours post-transfusion
Symptoms
Dyspnea
Cyanosis
Hypotension
Pulmonary edema
Fever
Treatment
Oxygen
Ventilation support
Prevention
Male-only plasma policy
10. TACO (Transfusion-Associated Circulatory Overload)
Cause
Fluid overload (non-immune)
Pathophysiology
Heart cannot handle increased volume
Leads to CHF and pulmonary edema
Symptoms
Dyspnea
Hypertension
Tachycardia
Edema
Rales
Treatment
Stop transfusion
Oxygen
Diuretics
Sit patient upright
At-Risk Patients
Elderly
Infants
Cardiac patients
11. Transfusion-Associated GVHD
Cause
Donor T-cells attack recipient
Requirements
HLA differences
Donor immune cells present
Recipient cannot reject them
Onset
8–10 days
Symptoms
Rash
Fever
Enterocolitis
Liver dysfunction
Pancytopenia
Outcome
>90% mortality
Prevention
Irradiated blood products
Leukoreduction is NOT sufficient
12. Other Complications
Transfusion-related sepsis
Massive transfusion complications:
Citrate toxicity
Electrolyte imbalances
Coagulopathy
Hypothermia
Platelet refractoriness
Post-transfusion purpura
Iron overload
13. Clinical Evaluation (Nursing Role)
Steps
Stop transfusion
Treat symptoms
Notify physician & blood bank
Collect:
EDTA blood sample
Urine sample
Send:
Blood bag & tubing
Documentation
Recheck vitals
14. Laboratory Evaluation
Basic Work-Up (ALL reactions)
Purpose
Detect hemolytic reactions
Steps
Clerical check
Visual hemolysis check
DAT
Repeat ABO typing
Urine hemoglobin
Clerical Check
Correct patient?
Correct blood unit?
Visual Hemolysis
Pink/red → acute hemolysis
Yellow → delayed hemolysis
DAT
Detect coated RBCs
Look for mixed-field reactions
15. If Basic Work-Up is Negative
No further testing
Wait for pathologist approval
16. If Basic Work-Up is Positive
Extended Work-Up
Repeat ABO/Rh
Repeat antibody screen
Repeat crossmatch
If DAT Positive
Perform elution
Elution Interpretation
All cells negative → drug effect/non-specific
All cells positive → autoantibody/high-incidence antigen
A or B cells only → ABO antibody
Panel pattern → alloantibody
Additional Testing
Culture donor unit
Test for:
HLA antibodies
Anti-IgA
Hemolysis labs:
↓ Haptoglobin
↑ Bilirubin
↑ LDH
↑ Reticulocytes
Spherocytes
17. Key Concepts to Remember
AHTR = ABO mismatch = intravascular hemolysis
DHTR = delayed IgG response = extravascular hemolysis
Most reactions are non-hemolytic
Always:
Stop transfusion first
Perform basic work-up
DAT + elution = key diagnostic tools
Prevention focuses on:
Proper identification
Leukoreduction
Irradiation
Careful monitoring
Study Guide: QC & Regulations in Transfusion Medicine
Objective 1: FDA’s Five Layers of Safety
The FDA ensures blood safety through five key layers:
1. Donor Screening
Evaluation before donation
Identifies risk factors (medical history, behaviors)
Prevents unsafe individuals from donating
2. Blood Testing
Each unit is tested for:
Infectious diseases
Blood type compatibility
Ensures safety of collected blood
3. Deferred Donor Lists
Records individuals who are not eligible to donate
Prevents future donations from unsafe donors
4. Quarantine
Blood units are held until:
Testing is completed
Safety is confirmed
Prevents release of unsafe blood
5. Recognition and Reporting of Problems
Identification of:
Errors
Deficiencies
Adverse events
Reporting to regulatory agencies is required
Objective 2: Federal Regulations and Risk Management
Regulatory Authority
Based on:
Public Health Service Act
Federal Food, Drug, and Cosmetic Act
Blood is classified as a biological product
Oversight by Center for Biologics Evaluation and Research (CBER)
Manufacturing Blood Products
Includes:
Collection
Processing
Testing
Distribution
Must follow:
Current Good Manufacturing Practices (cGMP)
Regulations Dissemination
Published in the Federal Register
Guidance documents:
Level 1: new or controversial regulations
Level 2: minor changes to existing regulations
Registration and Licensing
Facilities must:
Register with the FDA
List products they manufacture
Applies to:
Blood collection centers
Hospital blood banks
Testing labs
Storage/distribution centers
License required for interstate distribution
Inspections
Conducted:
Before licensing
Every 2 years after
Evaluate:
Quality assurance
Donor eligibility system
Testing system
Quarantine/inventory management
Processing systems
Additional inspections may occur from other agencies
Violations
Possible FDA actions:
Warning letter
License suspension or revocation
Legal action (injunction, seizure, prosecution)
Adverse Event Reporting
Must report to CBER:
Transfusion-related fatalities
Donation-related deaths
Medicolegal Aspects of Transfusion Medicine
Definition
Legal consequences of transfusion-related injury or death
Common Legal Issues
ABO errors
TRALI
Patient privacy violations
Transfusion-transmitted disease
Lack of informed consent
Torts
Improper interactions leading to harm:
Battery
Negligence
Liability
Emotional distress
Invasion of privacy
Risk Management Strategies
Donor-related
Pre-donation screening
Testing of donor units
Patient safety
Notify recipients if unsafe blood was given
Proper labeling and distribution
Clinical practice
Informed consent
Documentation of testing
Appropriate transfusion indications
Prevention of physician negligence
Ethical Principles
Autonomy: patient decision-making
Beneficence: act in patient’s best interest
Justice: fair and equal treatment
Objective 3: Compliance vs Quality Management
Quality Management (QM)
Continuous process
Focuses on maintaining and improving quality
Keeps facility inspection-ready
Compliance
Correction of identified deficiencies
Measured during inspections
Represents a single point in time
Key Distinction
Compliance alone does not ensure quality
QM is ongoing and proactive
Objective 4: 12 Quality System Essentials (QSEs)
1. Organization
Defines structure and relationships
Includes:
Medical director responsibilities
Communication pathways
Emergency preparation
2. Customer Focus
Customers include:
Patients
Physicians/nurses
Donors
Focus is on meeting their needs
3. Personnel
Defines:
Qualifications
Training
Competency testing
Continuing education
4. Equipment
Covers:
Selection and validation
Use and monitoring
Maintenance and calibration
Record keeping
5. Purchasing and Inventory
Ensures:
Supplier qualification
Vendor selection
Inspection of incoming materials
Ongoing evaluation
6. Process Management
Most comprehensive QSE
Ensures:
Controlled procedures
Quality of blood and components
Includes:
Quality control
Sterility
Identification and traceability
Storage and handling
Labeling
Testing
Timeliness
Requires adherence to cGMP
7. Documents and Records
Principle:
If it is not documented, it was not done
Includes:
Control and format
Review and updates
Proper use
Retention
8. Information Management
Management of patient and donor data
Ensures:
Confidentiality
Data integrity
9. Nonconformance Management
Handles:
Errors
Adverse events
Transfusion reactions
Transfusion-transmitted diseases
Requires:
Identification
Documentation
Reporting to FDA when necessary
10. Assessments
Internal
Routine audits
Monitoring trends
External
Inspections by FDA, AABB, CAP, TJC, CMS
Requires correction of deficiencies
11. Continual Improvement
Focus:
Prevent future problems
Methods:
Error tracking
Data analysis
PDCA cycle (Plan, Do, Check, Act)
12. Facilities and Safety
Ensures:
Safe work environment
Includes:
Environmental controls
Fire and electrical safety
Infection control
Biohazard disposal
Disaster preparedness
Requires staff training and documentation
Quality Concepts
Quality Control (QC)
Detects process failures during routine operations
Quality Assurance (QA)
Planned actions to ensure systems function properly
Quality Systems (QS)
Comprehensive framework integrating QC and QA
Key Points for Review
FDA safety relies on five layers working together
CBER oversees blood safety
cGMP is essential for process control
Legal risk arises from errors, lack of documentation, and poor consent
Quality management is continuous; compliance is periodic
Know all 12 QSEs, especially process management